drugset

drugset / Trial / NCT01874028

A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients

NCT01874028 ↗

Phase 1 Completed 20 enrolled Univar BV Aptiv Solutions · collab

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the effects of a single dose of trientine in children ≥6 years and adult patients with Wilson's disease.

Timeline

Start: 2013-05
Primary completion: 2014-03
Completion: 2014-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	trientine	Unknown	300 mg	Oral

Indications